In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAMES: Azamedac; Azamune; Azasan (aaiPharma); Azatrilem; Imuprin; Imuran (Prometheus); Imurek; Imurel; Thioprine
- INDICATIONS: Lupus nephritis, psoriatic arthritis, rheumatoid arthritis, autoimmune diseases, as an adjunct for the prevention of rejection in kidney transplant patients
- CLASS: Antimetabolite, Disease-modifying antirheumatic drug (DMARD), Immunosuppressant, Purine analog
- HALF-LIFE: 12 minutes
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Allopurinol, Aminosalicylates, Balsalazide, Benazepril, Captopril, Chlorambucil, Co-Trimoxazole, Cyclophosphamide, Cyclosporine, Enalapril, Febuxostat, Fosinopril, Hemophilus B Vaccine, Imidapril, Lisinopril, Mesalamine, Mycophenolate, Natalizumab, Olsalazine, Quinapril, Ramipril, Ribavirin, Sulfamethoxazole, Tofacitinib, Trimethoprim, Typhoid Vaccine, Vaccines, Warfarin, Yellow Fever Vaccine
- See adverse reactions attributed to class:
Patients receiving immunosuppressants, including azathioprine, are at increased risk of developing lymphoma and other malignancies, particularly of the skin.
MALIGNANCY
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 11/02/2024
